Cytogam
Payments companies reported to CMS as associated with Cytogam. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cytogam, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cytogam
These are the largest totals companies reported as associated with Cytogam. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sarah Sunshine | Chicago, IL | Ophthalmology | $23,200.00 |
| John Mcdyer | Baltimore, MD | Pulmonary Disease | $10,007.49 |
| Martin Zamora | Orlando, FL | Critical Care Medicine (Internal Medicine) | $9,367.74 |
| Jay Fishman | Boston, MA | Infectious Disease | $9,291.32 |
| Timothy Pruett | Charlottesville, VA | Transplant Surgery | $8,323.80 |
| Yoichiro Natori | Miami, FL | Infectious Disease | $8,282.48 |
| Camille Kotton | Boston, MA | Infectious Disease | $7,840.96 |
| Lorenzo Zaffiri | Atlanta, GA | Pulmonary Disease | $5,417.05 |
| Robert Gottlieb | Dallas, TX | Advanced Heart Failure and Transplant Cardiology | $5,327.60 |
| Erika Lease | Seattle, WA | Pulmonary Disease | $5,100.00 |
Prescribed Cytogam?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.